INTERNATIONAL MEDICATION SYSTEMS LIMITED

Alembic Pharmaceuticals Secures FDA Approval for Phytonadione Injectable Emulsion in $44 Million Market

- Alembic Pharmaceuticals received FDA approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe, therapeutically equivalent to the reference drug. - The approved product targets hypoprothrombinemia due to vitamin K deficiency and vitamin K-deficiency bleeding in neonates, entering a $44 million market. - This approval brings Alembic's total ANDA approvals to 225, positioning the company to capitalize on the growing generic sterile injectables market projected to reach $251.03 billion by 2030.